The infants diagnosed with SVT are treated with antiarrhythmic medication to prevent the recurrence of SVT. This prospective observational cohort study evaluates efficacy and safety of shortening duration of antiarrhythmic medication to four months in infants with SVT. Primary outcome is incidence of recurrent SVT in infants after 4 months of antiarrhythmic medication compared to retrospectively reviewed cohort.
Study Type
OBSERVATIONAL
Enrollment
107
3 mg/kg/d, divided in four doses when age less than 3 months and in three doses when age more than 3 months
80 mg/m2/d
Single dose of 10 mg/kg/d 10-14 days, 5 mg/kg/d
Central Finland Central Hospital
Jyväskylä, Central Finland, Finland
Kajaani Central Hospital
Kajaani, Kainuu, Finland
Recurrence of SVT after antiarrhythmic medication
Time frame: 1 year follow-up
Proportion of participants with treatment failure
Time frame: 4 months of antiarrhythmic medication
Prevalence of adverse events
Time frame: 4 months of antiarrhythmic medication
Recurrence of SVT after one year follow-up
Time frame: 5 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Hämeenlinna Central Hospital
Hämeenlinna, Kanta-Häme, Finland
Kokkola Central Hopsital
Kokkola, Keski-Pohjanmaa, Finland
Lapland Central Hospital
Rovaniemi, Lapland, Finland
Oulu University Hospital
Oulu, North Ostrobothnia, Finland
Kuopio University Hospital
Kuopio, Northern Savonia, Finland
Lahti Central Hospital
Lahti, Paijat-Hame Region, Finland
Tampere University Hospital
Tampere, Pirkanmaa, Finland
Vaasa Central Hospital
Vaasa, Pohjanmaa, Finland
...and 8 more locations